Change over period: —
NSE · SUDEEPPHRM
SUDEEPPHRM
-10.6% from the 52-week high · +126.8% above the low
Sudeep Pharma Ltd manufactures pharmaceutical formulations and health care products for domestic and international markets. The company produces tablets, capsules, syrups, and specialized formulations. Its operations cover research, development, quality control, and regulatory compliance. By delivering safe and effective products, it contributes to healthcare solutions across multiple therapeutic segments.
The short version. SUDEEPPHRM reported revenue of ₹197 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹52 crore (up 13.0% year on year). Return on equity was 19.6% in Mar 2026. Promoter holding was 76.15% in Sep 2026, up 0.00 points over 5 quarters.
1 · The price
How has the stock traded?
SUDEEPPHRM trades 10.6% below its 52-week high and 126.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹197 cr.
Sep 2026 net profit of ₹52 cr.
1.8 pts lower than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Revenue | 197 | 158 | 182 | 172 | 163 |
| Net profit | 52 | 41 | 49 | 48 | 46 |
| Net margin % | 26.3 | 25.6 | 26.8 | 27.6 | 28.1 |
| EPS (₹) | 4.59 | 3.59 | 4.33 | 4.22 | 4.05 |
Annual
| FY2026 | |
|---|---|
| Revenue | 642 |
| Net profit | 173 |
| Net margin % | 26.9 |
| EPS (₹) | 15.31 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 19.6% in Mar 2026; debt to equity is 0.17.
Profitability · 1 years
Returns and margins
| Mar 2026 | |
|---|---|
| Return on equity % | 19.6 |
| Return on capital % | 24.2 |
| EBITDA margin % | 37.3 |
| Net margin % | 25.8 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 5 quarters.
Up 1.39 pts over 5 quarters.
Down 0.71 pts over 5 quarters.
+16 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|
| Promoter | 76.15 | 76.15 | 76.15 | 76.15 | 76.15 | 0.0 |
| FII | 1.54 | 1.67 | 1.55 | 1.81 | 2.93 | +1.39 |
| DII | 14.76 | 17.6 | 18.11 | 15.65 | 14.05 | -0.71 |
| Public | 7.54 | 4.58 | 4.18 | 6.39 | 6.87 | -0.67 |
Mutual fund holdings · Oct 2026
37 schemes hold this stock
21 the month before.
- SBI Comma Fund6.35% of NAV
- SBI Healthcare Opportunities Fund2.39% of NAV
- EDELWEISS RECENTLY LISTED IPO FUND2.37% of NAV
- THE WEALTH COMPANY SMALL CAP FUND1.35% of NAV
- PGIM INDIA SMALL CAP FUND1.22% of NAV
- SBI MNC Fund1.2% of NAV
- SBI RETIREMENT BENEFIT FUND - AGGRESSIVE PLAN1.16% of NAV
- UTI - Healthcare Fund0.97% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SUDEEPPHRM are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SUDEEPPHRM
What is the SUDEEPPHRM share price?
SUDEEPPHRM (SUDEEPPHRM) last closed at ₹1,212.10, up 0.82% on the day. Its 52-week range is ₹530.00 to ₹1,344.20.
What is the market cap of SUDEEPPHRM?
SUDEEPPHRM has a market capitalisation of about ₹13,571 crore. Its price-to-earnings ratio is 72.3.
How are SUDEEPPHRM's latest results?
SUDEEPPHRM reported revenue of ₹197 crore for Sep 2026, up 20.9% from a year earlier. Net profit was ₹52 crore (up 13.0% year on year). Return on equity was 19.6% in Mar 2026. Promoter holding was 76.15% in Sep 2026, up 0.00 points over 5 quarters.
Who owns SUDEEPPHRM?
As of Sep 2026, shareholding was: Promoter 76.15%, FII 2.93%, DII 14.05%, Public 6.87%.
How many mutual funds hold SUDEEPPHRM?
37 mutual fund schemes held SUDEEPPHRM in October 2026. That compares with 21 the month before.
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.